

Effect of an oral chondroprotector (HyalORAL®) in the preventive treatment of elbow dysplasia in labradors

Simón Martí Angulo,

Núria García López,

Ana Díaz Ramos

Fundación Once del Perro Guía (FOPG)



hyalORAL®



FOPG y Pharmadiet

- Pharmadiet is a company integrated in Opko Health Company, based in Barcelona, which since 1992 has researched and developed nutritional supplements, scientifically proven, aimed to correct articular degenerative processes, both in humans and in companion animals.
- The FOPG has carried out a clinical study in collaboration with Pharmadiet, in order to scientifically demonstrate the effect of a nutritional supplement, Hyaloral®, in the prevention and treatment of elbow dysplasia in labrador dogs.

Goals

1. **Prevention**: to study the incidence of elbow dysplasia in labradors treated with an oral chondroprotector prophylactically against untreated dogs.
2. **Efficacy of treatment**: to carry out a clinical follow-up of animals diagnosed with joint dysplasia (treated vs. untreated).



Material & Methods

DESIGN & TREATMENT

- **Prophylactic and comparative exploratory study.**
- **105 dogs** of the 3-month-old Labrador Retriever breed.
- **Two groups:**
 - Control: Specific feeding without supplementation
 - Treatment: Specific feeding + **supplementation with Hyaloral**
 - **Both groups took the same food**

Material & Methods I

Inclusion criteria

- Healthy animals of 3 months of age and of internal litters.
- Male and female homogenization (no exclusion by sex).
- All the animals were castrated during the study.
- Vaccinated animals (octavalent and pneumodog).
- Pure Labrador retriever breed.

Exclusion criteria

- Animals with any disease that could confuse or interfere with the evaluation of efficacy.
- Animals with trauma or previous fracture (the animals that presented them during the process were removed).
- Animals with concomitant chondroprotective medication
- Selected animals for breeding.


Material & Methods II

- **Supplement** (Hyaloral[®]): tablets based on hyaluronic acid (20 mg), enzymatically hydrolyzed collagen (2.2 g), crystallized glucosamine (312.5 mg *), chondroitin sulfate (200 mg) and gamma oryzanol (100 mg), dosed according to the weight.

* equivalent to 500mg of crystallized glucosamine sulfate

- 4 follow-up visits in months 3, 6, 12 and 20.
- At 20 months the study ends.
- Animals with radiological signs of elbow and / or hip dysplasia at 12 months → unfit and retired as a guide dog.
 - The last follow-up visit (20 months) was carried out in order to assess the effectiveness of the Treatment.

Material & Methods III



Conclusions I

Treatment with Hyaluronic Acid, Enzymatically Hydrolysed Collagen, Glucosamine, Chondroitin Sulfate and Gamma Oryzanol (Hyaloral®):

PREVENTION

- In the control group, an incidence of 33.3% is confirmed (incidence of elbow dysplasia in Labrador dogs is 30%, in the normal population).
 - **In the treated group, Hyaloral® demonstrates:**
 - A significantly reduced incidence, up to 18.5%.
 - Preventive action in the appearance of joint dysplasia in the treated group versus the control group
 - Lower rejection of animals for training in the FOPG.

Conclusions II

Treatment with Hyaluronic Acid, Enzymatically Hydrolysed Collagen, Glucosamine, Chondroitin Sulfate and Gamma Oryzanol (Hyaloral®):

EFFICACY IN THE TREATMENT OF DYSPLASIA

- **In the treated group, Hyaloral® demonstrates:**
 - Significantly improves symptoms and joint signs, both elbow and hip.
 - Additive effect: the improvement is maintained until at least 2 years of age.
 - Disappearance of lameness at 20 months.
 - Improvement of mobility.
 - Reduction of swelling Improvement of the quality of life.
 - Commitment to animal welfare.
 - No side effects

PUBLICATIONS

- Poster presented at the XIII GEVO 2013 Conference. Gijón, April 2013.
- Study accepted for publication in the Journal of Veterinary Science (JVS)
On July 04, 2014.
Published on July 18, 2014